Pacific Biosciences of California, Inc.
PACB· Nasdaq
PACBPacific Biosciences of California, Inc.
Released Nov 7, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0001299130-24-000183
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $39.97M | $55.69M | $32.31M | $34.89M |
| Net Income | -$60.73M | -$66.87M | -$76.97M | $16.54M |
| EPS Diluted |
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR
| -$0.22 |
| -$0.26 |
| -$0.34 |
| $0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
